Journal of Internal Medicine Concepts & Practice ›› 2023, Vol. 18 ›› Issue (04): 292-296.doi: 10.16138/j.1673-6087.2023.04.017
• Lecture • Previous Articles Next Articles
ZHENG Sichang, ZHOU Weiwei, WANG Weiqing(
)
Received:2023-05-31
Online:2023-08-30
Published:2024-01-09
CLC Number:
ZHENG Sichang, ZHOU Weiwei, WANG Weiqing. Therapy progress for acromegaly[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 292-296.
| 研究 | 药物剂量 | 病例数（n） | 抑制切点 | 治疗目标 | 预测价值 | 结论 |
|---|---|---|---|---|---|---|
| Karavitaki等[ | 100 μg s.c. 6 h | 30 | Nadir GH<5.25 mU/L | GH<5 mU/L | PPV 94%，NPV 100% | 推荐 |
| Biermasz等[ | 50 μg i.v. 3 h | 18 | Nadir GH<5 mU/L | GH<5 mU/L IGF-1正常 | PPV 73%，NPV 57% | 推荐 |
| Gilbert等[ | 50 μg s.c. 6 h | 33 | Nadir GH<5 mU/L | GH<5 mU/L | 灵敏度80%，特异度83% | 推荐 |
| Bandgar等[ | 50 μg s.c. 6 h | 10 | Nadir GH<1 μg/L | Nadir GH<1 μg/L IGF-1正常 | PPV 100%，NPV 83% | 推荐 |
| Wang等[ | 100 μg s.c. 6 h | 67 | GH降低86.63%； GH降低90.51% | GH<2.5 μg/L或降低75%； 肿瘤缩小 | 灵敏度93.8% 特异度85.7%； 灵敏度84.8% 特异度87.5% | 推荐 |
| Colao等[ | 100 μg s.c. 6 h | 68 | mGH降低50% | GH<5 μg/L | PPV 43%，NPV 78% | 不推荐 |
| de Herder等[ | 50 μg s.c. 8 h | 24 | mGH降低50%； mGH降低75%； Nadir GH<1.1 μg/L； Nadir GH<2 μg/L； | IGF-1正常 | PPV 58%，NPV 100%； PPV 73%，NPV 77%； PPV 65%，NPV 69%； PPV 82%，NPV 46% | 不推荐 |
| Pokrajac等[ | 50/100 μg s.c. 9 h | 42 | Nadir GH<5 mU/L； GH降低75% | GH<5 mU/L IGF-1正常 | PPV 82%，NPV 50%； PPV 72%，NPV 40% | 不推荐 |
| Carlsen等[ | 50 μg s.c. 4 h | 31 | GH降低50% | GH<2 mU/L IGF-1正常 | 可预测GH降低， 无法预测肿瘤缩小 | 不推荐 |
| [1] |
Colao A, Grasso LFS, Giustina A, et al. Acromegaly[J]. Nat Rev Dis Primers, 2019, 5(1): 20.
doi: 10.1038/s41572-019-0071-6 pmid: 30899019 |
| [2] |
Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes[J]. Nat Rev Endocrinol, 2018, 14(9): 552-561.
doi: 10.1038/s41574-018-0058-5 pmid: 30050156 |
| [3] | 中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 751-760. |
| [4] |
Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications[J]. Nat Rev Endocrinol, 2010, 6(9): 515-525.
doi: 10.1038/nrendo.2010.123 pmid: 20664532 |
| [5] |
Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas[J]. JAMA, 2023, 329(16): 1386-1398.
doi: 10.1001/jama.2023.5444 URL |
| [6] |
Geer EB. Medical therapy for refractory pituitary adenomas[J]. Pituitary, 2023, 26(3): 303-306.
doi: 10.1007/s11102-023-01320-9 |
| [7] |
Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly[J]. PLoS One, 2012, 7(5): e36411.
doi: 10.1371/journal.pone.0036411 URL |
| [8] |
Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments[J]. J Clin Endocrinol Metab, 2014, 99(5): 1825-1833.
doi: 10.1210/jc.2013-3757 pmid: 24606084 |
| [9] |
Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study[J]. J Clin Endocrinol Metab, 2014, 99(3): 791-799.
doi: 10.1210/jc.2013-2480 pmid: 24423324 |
| [10] |
Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase Ⅲ trial[J]. J Clin Endocrinol Metab, 2015, 100(4): 1699-1708.
doi: 10.1210/jc.2014-4113 URL |
| [11] |
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice[J]. Front Neuroendocrinol, 2013, 34(3): 228-252.
doi: 10.1016/j.yfrne.2013.07.005 URL |
| [12] |
Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly[J]. Endocrine, 2016, 53(1): 210-219.
doi: 10.1007/s12020-016-0895-8 pmid: 26906713 |
| [13] |
Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis[J]. J Clin Endocrinol Metab, 2011, 96(5): 1327-1335.
doi: 10.1210/jc.2010-2443 pmid: 21325455 |
| [14] |
Kuhn E, Chanson P. Cabergoline in acromegaly[J]. Pituitary. 2017, 20(1): 121-128.
doi: 10.1007/s11102-016-0782-6 pmid: 28025719 |
| [15] |
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs[J]. JAMA Intern Med, 2014, 174(12): 1930-1933.
doi: 10.1001/jamainternmed.2014.5262 pmid: 25329919 |
| [16] |
Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly[J]. Endocr Rev, 2002, 23(5): 623-646.
doi: 10.1210/er.2001-0022 pmid: 12372843 |
| [17] |
van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist[J]. Lancet, 2001, 358(9295): 1754-1759.
doi: 10.1016/s0140-6736(01)06844-1 pmid: 11734231 |
| [18] |
Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY[J]. Endocr Pract, 2015, 21(3): 264-274.
doi: 10.4158/EP14330.OR pmid: 25370326 |
| [19] |
Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly[J]. Pituitary, 2017, 20(1): 129-135.
doi: 10.1007/s11102-016-0753-y pmid: 27631335 |
| [20] |
Fleseriu M, Führer-Sakel D, van der Lely AJ, et al. More than a decade of real-world experience of pegvisomant for acromegaly[J]. Eur J Endocrinol, 2021, 185(4): 525-538.
doi: 10.1530/EJE-21-0239 pmid: 34342594 |
| [21] |
Bengtsson D, Schrøder HD, Andersen M, et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide[J]. J Clin Endocrinol Metab, 2015, 100(4): 1689-1698.
doi: 10.1210/jc.2014-4350 pmid: 25646794 |
| [22] |
Burman P, Trouillas J, Losa M, et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients[J]. Eur J Endocrinol, 2022, 187(4): 593-605.
doi: 10.1530/EJE-22-0440 pmid: 36018781 |
| [23] |
Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas[J]. Eur J Endocrinol, 2018, 178(1): G1-G24.
doi: 10.1530/EJE-17-0796 URL |
| [24] | 中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版)[J]. 中华医学杂志, 2021, 101(27): 2115-2126. |
| [25] |
Majd N, Waguespack SG, Janku F, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase Ⅱ study[J]. J Immunother Cancer, 2020, 8(2): e001532.
doi: 10.1136/jitc-2020-001532 URL |
| [26] |
Ilie MD, Villa C, Cuny T, et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study[J]. Eur J Endocrinol, 2022, 187(5): 685-696.
doi: 10.1530/EJE-22-0647 pmid: 36111659 |
| [27] |
Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly[J]. J Clin Endocrinol Metab, 2013, 98(1): E66-E71.
doi: 10.1210/jc.2012-2609 URL |
| [28] |
Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs[J]. J Endocrinol Invest, 2013, 36(1): 38-43.
doi: 10.3275/8305 pmid: 22472799 |
| [29] |
Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study[J]. Eur J Endocrinol, 2016, 174(2): 241-250.
doi: 10.1530/EJE-15-0832 pmid: 26586796 |
| [30] |
Chiloiro S, Giampietro A, Mirra F, et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response[J]. Eur J Endocrinol, 2021, 184(2): 217-229.
doi: 10.1530/EJE-20-0767 pmid: 33136550 |
| [31] |
Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression[J]. J Clin Endocrinol Metab, 2019, 104(3): 915-924.
doi: 10.1210/jc.2018-01524 pmid: 30346538 |
| [32] |
Venegas-Moreno E, Flores-Martinez A, Dios E, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly[J]. Cell Mol Med, 2019, 23(5): 3088-3096.
doi: 10.1111/jcmm.2019.23.issue-5 URL |
| [33] |
Puig-Domingo M, Gil J, Sampedro-Nuñez M, et al. Molecular profiling for acromegaly treatment: a validation study[J]. Endocr Relat Cancer, 2020, 27(6): 375-389.
doi: 10.1530/ERC-18-0565 URL |
| [34] |
Fusco A, Zatelli MC, Bianchi A, et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas[J]. J Clin Endocrinol Metab, 2008, 93(7): 2746-2750.
doi: 10.1210/jc.2008-0126 URL |
| [35] |
Kasuki L, Wildemberg LE, Neto LV, et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern[J]. Eur J Endocrinol, 2013, 169(2): 217-223.
doi: 10.1530/EJE-13-0349 pmid: 23749849 |
| [36] |
Quabbe HJ, Plöckinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly[J]. J Clin Endocrinol Metab, 1989, 68(5): 873-881.
doi: 10.1210/jcem-68-5-873 URL |
| [37] | Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly[J]. J Clin Endocrinol Metab, 1996, 81(6): 2356-2362. |
| [38] |
Biermasz NR, Pereira AM, Smit JW, et al. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly[J]. Growth Horm IGF Res, 2005, 15(3): 200-206.
pmid: 15935982 |
| [39] |
Gilbert JA, Miell JP, Chambers SM, et al. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly[J]. Clin Endocrinol (Oxf), 2005, 62(6): 742-747.
doi: 10.1111/cen.2005.62.issue-6 URL |
| [40] |
Karavitaki N, Botusan I, Radian S, et al. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly[J]. Clin Endocrinol (Oxf), 2005, 62(3): 282-288.
doi: 10.1111/cen.2005.62.issue-3 URL |
| [41] |
de Herder WW, Taal HR, Uitterlinden P, et al. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly[J]. Eur J Endocrinol, 2005, 153(1): 67-71.
pmid: 15994747 |
| [42] |
Pokrajac A, Claridge AG, Shakoor SK, et al. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly[J]. Eur J Endocrinol, 2006, 154(2): 267-274.
pmid: 16452540 |
| [43] |
Carlsen SM, Svartberg J, Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure[J]. Clin Endocrinol (Oxf), 2011, 74(6): 736-743.
doi: 10.1111/cen.2011.74.issue-6 URL |
| [44] |
Wang M, Shen M, He W, et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly[J]. Endocr J, 2016, 63(9): 819-834.
doi: 10.1507/endocrj.EJ16-0175 pmid: 27432816 |
| [45] | Bandgar TR, Sarathi V, Shivane V, et al. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly[J]. J Postograd Med, 2010, 56(1): 7-11. |
| [46] |
Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly[J]. Mayo Clin Proc, 2022, 97(2): 333-346.
doi: 10.1016/j.mayocp.2021.11.007 pmid: 35120696 |
| [47] |
Nunes VS, Correa JM, Puga ME, et al. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system[J]. Pituitary, 2015, 18(4): 500-508.
doi: 10.1007/s11102-014-0602-9 pmid: 25261979 |
| [48] |
Papaioannou C, Druce M. Preoperative medical treatments and surgical approaches for acromegaly[J]. Clin Endocrinol (Oxf), 2023, 98(1): 14-31.
doi: 10.1111/cen.v98.1 URL |
| [49] |
Puig-Domingo M, Soto A, Venegas E, et al. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice[J]. Endocrinol Nutr, 2016, 63(8): 397-408.
doi: 10.1016/j.endonu.2016.05.010 pmid: 27448708 |
| [50] |
Lim DS, Fleseriu M. The role of combination medical therapy in the treatment of acromegaly[J]. Pituitary, 2017, 20(1): 136-148.
doi: 10.1007/s11102-016-0737-y pmid: 27522663 |
| [51] |
Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR[J]. Pituitary, 2011, 14(2): 148-156.
doi: 10.1007/s11102-010-0272-1 pmid: 21104199 |
| [52] |
Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature[J]. Endocr J, 2013, 60(4): 507-515.
pmid: 23291436 |
| [53] |
Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly[J]. Lancet, 2005, 365(9471): 1644-1646.
doi: 10.1016/S0140-6736(05)63011-5 pmid: 15885297 |
| [54] |
Strasburger CJ, Mattsson A, Wilton P, et al. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant[J]. Eur J Endocrinol, 2018, 178(4): 321-329.
doi: 10.1530/EJE-17-0996 pmid: 29371335 |
| [55] |
Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial[J]. J Clin Endocrinol Metab, 2012, 97(4): 1187-1193.
doi: 10.1210/jc.2011-2603 pmid: 22278424 |
| [56] |
Bernabeu I, Alvarez-Escolá C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly[J]. Pituitary, 2013, 16(1): 101-108.
doi: 10.1007/s11102-012-0382-z pmid: 22396133 |
| [1] | Chinese Society of Endocrinology. Guidelines for clinical management of novel coronavirus infection in patients with diabetes insipidus [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(01): 25-27. |
| [2] | Chinese Society of Endocrinology. Guidelines for clinical management of novel coronavirus infection in pituitary disease [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(01): 18-21. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
